SciELO - Scientific Electronic Library Online

 
vol.84 número3Comparación de valores de temperatura obtenidos con termómetro ótico digital y con termómetros axilar y rectal de mercurio en menores de 5 añosFusión esplenogonadal como causa de masa testicular pediátrica: Caso clínico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista chilena de pediatría

versión impresa ISSN 0370-4106

Resumen

BANCALARI M, ALDO; SCHADE Y, RICARDO; PENA Z, RUBÉN  y  PAVEZ P, NICOLÁS. Intravitreal bevacizumab as treatment for retinopathy of prematurity. Rev. chil. pediatr. [online]. 2013, vol.84, n.3, pp.300-307. ISSN 0370-4106.  http://dx.doi.org/10.4067/S0370-41062013000300008.

Introduction: Standard treatment of threshold Retinopathy of Prematurity (ROP) is laser photocoagulation (LPC). Recently, bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor has been used with positive results. Objective: To communicate the response to treatment with bevacizumab in premature newborns with threshold retinopathy. Patients and Method: Very low birth weight (VLBW) infants that received bevacizumab, in monotherapy or associated with LPC, as treatment for threshold ROP, were analyzed. Response to treatment, reinterventions and complications were evaluated. Results: 17 VLBW infants were analyzed with mean gestational age 26.4 ± 1.7 weeks and mean birth weight 850 ± 141 g. All 6 patients treated with bevacizumab in association with LPC did not require reintervention. Of the 11 neonates that only received bevacizumab, 36.3% needed further treatment. Conclusions: Bevacizumab could be an effective therapy for treatment of threshold ROP. In our experience it presented advantages compared with LPC, since therapy can be carried out without transferring the patient and with no use of general anesthetics. No short term complications were observed with the use of bevacizumab in treated patients.

Palabras clave : Retinopathy of prematurity; intravitreal injections; bevacizumab; vascular endothelial growth factor.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons